The tweet was deleted by the author.
But we saved everything 🙂.
MeiraGTx is set to participate in Chardan's 9th Annual Genetic Medicines Conference on October 21.
The company's CEO, Alexandria Forbes, Ph.D., will address the latest advancements in genetic medicines tailored for ocular and neurodegenerative diseases.
Attendees can expect insights into cutting-edge treatments that MeiraGTx is pursuing, aiming to push the boundaries of genetic therapies.
The conference offers a platform for leading voices in the field to discuss crucial developments and future directions.
MeiraGTx’s participation in the conference builds upon its recent progress in gene therapy for neurodegenerative disorders, highlighted by the company’s RMAT status for its Parkinson’s program as detailed in the advancement of MeiraGTx's gene therapy for Parkinson's disease. The company’s efforts to enhance gene therapy efficiency through AI-driven promoter activity also continue to set industry benchmarks, underscoring their commitment to innovation in the sector.